Latest Kaiser Health News Stories
Amid questions about the accuracy of the COVID-19 antibody tests flooding the market — and the usefulness of the results they provide — the FDA has belatedly stepped in to try to rein in the chaos.
Some communities considered community antibody testing as a way out of lockdown. But they’ve pulled back as they realized antibody testing is the Wild West in an oversight vacuum.
HHS said this test would “save personal protective equipment.” But Abbott’s very design ― devised for mobile testing — means those working with specimens need even more protection, experts warn.
Many Americans order drugs from Canada and other countries because they are cheaper, but U.S. authorities appear to be cracking down on the practice.
The politics of COVID-19 are pretty polarized, but health experts across the ideological spectrum agree: The U.S. will need more robust testing before it’s safe to relax social-distancing requirements. Meanwhile, President Donald Trump, Congress and the nation’s governors continue to spar over who should be responsible for what. Kimberly Leonard of Business Insider, Tami Luhby of CNN and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
As efforts ramp up to collect blood plasma from the first survivors of COVID-19, families of critically ill patients are jockeying to obtain the still-unproven antibody treatment.
Josie and George Taylor of Everett, Washington, are two of the first people in the U.S. to recover from novel coronavirus infections after joining a clinical trial for the antiviral drug remdesivir.
States urgently need millions of tests, and the game changer they’ve been waiting on falls well short of what is needed, according to government documents obtained by KHN.
Pruebas no aprobadas por la FDA y varios informes cuestionables de Internet relacionados con pruebas de coronavirus, vacunas y curas “milagrosas” han estado circulando por las redes sociales.
Americans are worried about the novel coronavirus, so they are turning to the internet for solutions to stem their fears. Buyer, beware. It could be dangerous.
Desde la toma de la muestra con un hisopo hasta el paso final, expertos explican cómo se trata la muestra para COVID-19, y explican futuros tests rápidos que podrían arrojar un resultado en minutos.
A common complaint about the testing process is the long turnaround time for results.
Nationwide, testing for coronavirus is ramping up. But the supply of specialty swabs needed to collect potential coronavirus specimens can’t keep up with demand, creating a bottleneck in testing capabilities. So two top manufacturers are working with U.S. and Italian governments to increase production.
Los doctores Keith Jerome y Alex Greninger, de la Universidad de Washington, han supervisado la implementación de más de 4,000 pruebas de pacientes de todo el país.
Drs. Keith Jerome and Alex Greninger fast-tracked a test for the deadly new coronavirus weeks before it began spreading in the U.S. Their work has been key to detecting community transmission and ramping up the nation’s testing capacity.
A study ordered by the Food and Drug Administration failed to prove that Makena, the only drug approved to prevent premature birth, is effective. While a panel of experts has recommended withdrawing the drug’s approval, many doctors are wary.
SmileDirectClub and similar startup companies say they provide these services at what can be thousands of dollars less than office-visit teeth straightening, but proof is lacking and patients can be left with no recourse if problems arise.